brentuximab vedotin + bevacizumab

This combination therapy consists of **brentuximab vedotin**, a CD30-directed antibody-drug conjugate (ADC), and **bevacizumab**, a monoclonal antibody targeting vascular endothelial growth factor (VEGF). The regimen is being investigated by the **Masonic Cancer Center, University of Minnesota**, specifically for the treatment of men with refractory CD30-positive germ cell tumors (GCT). Brentuximab vedotin works by binding to CD30 on the surface of tumor cells, internalizing, and releasing the cytotoxic agent monomethyl auristatin E (MMAE), which disrupts the microtubule network. Bevacizumab complements this by binding to VEGF-A, thereby inhibiting tumor angiogenesis and potentially improving drug delivery or exerting direct anti-tumor effects. This combination is typically evaluated in patients who have progressed after standard platinum-based chemotherapy.

Brand names

Adcetris + Avastin

Other names

Brentuximab vedotin and bevacizumab combinationBV + Bev